Antibody Information
General Information of This Antibody (ID: ANTI0BQFXW)
| Antibody Name | huDS6 |
|||||
|---|---|---|---|---|---|---|
| Antigen Name | Carbonic anhydrase 6 (CA6) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QAQLVQSGAEVVKPGASVKMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGATNY
NQKFQGKATLTADTSSSTAYMQISSLTSEDSAVRFCARGDSVPFAYWGQGTLVTVSAAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
QAQLVQSGAEVVKPGASVKMSCKASGYTFTSYNMHWVKQTPGQGLEWIGYIYPGNGATNY
NQKFQGKATLTADTSSSTAYMQISSLTSEDSAVRFCARGDSVPFAYWGQGTLVTVSAAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Light Chain Sequence |
EIVLTQSPATMSASPGERVTITCSAHSSVSFMHWFQQKPGTSPKLWIYSTSSLASGVPAR
FGGSGSGTSYSLTISSMEAEDAATYYCQQRSSFPLTFGAGTKLELKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
EIVLTQSPATMSASPGERVTITCSAHSSVSFMHWFQQKPGTSPKLWIYSTSSLASGVPAR
FGGSGSGTSYSLTISSMEAEDAATYYCQQRSSFPLTFGAGTKLELKRTVAAPSVFIFPPS DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SAR566658 [Phase 2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligibility: Metastatic TNBC patients (≥18y, ECOG<2) with CA6-positive disease and 1-3 prior chemotherapy lines (must include anthracycline/taxane). Exclusions: active CNS metastases, prior maytansinoid/eribulin therapy, Grade ≥2 neuropathy, corneal disorders, CYP3A4 inhibitor use, or contraindications to ocular prophylaxis. Contraception required during/6 months post-treatment.
Click to Show/Hide
|
||||
| Administration Dosage |
Participants received SAR566658 90 milligram per square meter (mg/m^2) as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02984683 | Clinical Status | PHASE2 | ||
| Clinical Description |
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
|
||||
| Primary Endpoint |
Primary endpoints include IMP-related safety findings (Grade ≥3 eye disorders/peripheral neuropathy or Grade ≥4 TEAEs per NCI CTCAE v4.03) during Cycle 1-2 (21-day cycles) and objective response rate (CR+PR per RECIST 1.1) assessed every 6 weeks until progression.
|
||||
| Other Endpoint |
Secondary outcomes comprise disease control rate (CR+PR+SD≥3 months), duration of response, PFS, TTP, treatment-emergent AEs/SAEs up to 30 days post-treatment, keratopathies incidence (with prophylactic ocular measures), and anti-drug antibody development over 3 treatment cycles.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligibility: CA6-positive solid tumor patients (≥15% tumor cell staining) without standard therapy options. Exclusions: ECOG≥2, organ dysfunction, unresolved toxicities (Grade>1), recent antitumor therapy (<3 weeks washout), pulmonary/cardiac comorbidities, corneal disorders, CYP3A inhibitor use, or midazolam contraindications (for specific cohort). Contraception required.
Click to Show/Hide
|
||||
| Administration Dosage |
SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01156870 | Clinical Status | PHASE1 | ||
| Clinical Description |
Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors
|
||||
| Primary Endpoint |
Primary objectives include dose escalation to determine MTD of SAR566658 (3-week cycles) and evaluation of preliminary antitumor activity (assessed every 6 weeks), along with CYP3A enzyme interaction assessment using midazolam probe at Days 1 and 4.
|
||||
| Other Endpoint |
Secondary endpoints comprise comprehensive safety monitoring (NCI-CTCAE v4.03), PK profiling, immunogenicity assessment, antitumor response evaluation, CYP3A activity analysis (up to Cycle 2), and alternative dosing schedule safety (up to 2 years).
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT02984683 | Clinical Status | Phase 1 | ||
| Clinical Description |
Open-label phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic triple negative breast cancer.
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT01156870 | Clinical Status | Phase 1 | ||
| Clinical Description |
Dose escalation, safety and pharmacokinetic, first in man study, of SAR566658 administered as a single agent by intravenous infusion in adult patients with CA6-positive and refractory solid tumors.
|
||||
References